Global Cancer Immunotherapy Market 2018 Study of Top companies are Pfizer, AstraZeneca, Roche, Bayer, Amgen, Novartis, Bristol Mayers Squibb, Johnson & Johnson, Merck Group, Eli Lilly and Company, Celgene, Gilead Sciences, bluebird bio

The Cancer Immunotherapy Market report provides with CAGR value fluctuation during the forecast period of 2018-2025 for the market. The Cancer Immunotherapy Market is changing because of the key players and brands which make moves like developments, product launches, joint ventures, merges and accusations that in turns changes the view of the global face of Healthcare industry. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

The Global Cancer Immunotherapy Market is expected to reach USD 202.89 Billion by 2025, from USD 70.63 billion in 2017 growing at a CAGR of 14.1% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Download FREE PDF sample copy of this research report@ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-immunotherapy-market

Cancer immunotherapy (sometimes called immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies can be categorized as active, passive or hybrid (active and passive). These approaches exploit the fact that cancer cells often have molecules on their surface that can be detected by the immune system, known as tumor-associated antigens (TAAs); they are often proteins or other macromolecules (e.g. carbohydrates). Active immunotherapy directs the immune system to attack tumor cells by targeting TAAs. Passive immunotherapies enhance existing anti-tumor responses and include the use of monoclonal antibodies, lymphocytes and cytokines.

Global Cancer Immunotherapy MarketBy Product Type (Monoclonal Antibody, Immunomodulatory, Cell Therapies, Checkpoint Inhibitors, Vaccines), By Cancer Type (Lung Cancer, Melanoma, Breast Cancer, Head And Neck Cancer, Prostate Cancer, Colorectal Cancer, Multiple Myeloma), By End Users, By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)– Industry Trends and Forecast to 2025

Top Competitors:

Pfizer Inc,
Astrazeneca,
Hoffmann-La Roche LTd,
Bayer AG,
Amgen Inc,
Novartis AG,
Bristol Mayers Squibb,
Johnson and Johnson,
Merck KgaA,
Eli Lilly,
celgene Corp,
Gilead ,
bluebird bio Inc,
Celldex therapeutics,
SillaJen Inc,
IGNITE Immunotherapy,
Westeren oncolytics ltd,
PsiOxus Therapeutics,
MultiVir,
Vyriad,
Oncolys BioPharma Inc,
Cold genesys Inc,
Sorrento Therapeutics Inc,
Targovax,
Lokon therapeutics,
New-link genetics Corporation,
Ziopharma oncology,
Tessa therapeutics Pte Ltd,
Atara biotherapeutics,
Cellectis,
Oryx,
VCN Biosciences,
Orca Therapeutics B.V,
Daiichi Sankyo Co Ltd,
Ascend laboratories LLC, 
Transgene SA,
among others.

To Avail 10% Discount On This Report Mail Us on:- sopan.gedam@databridgemarketresearch.com

Major Market Drivers:

New technologies and combination product availability is expected to drive the market in the forecast period
Production of biosimilars and biobetters
Rising cancer suffering population
Increased investment in research and development of cancer immunotherapy
Downward pricing pressure owing to its commodity nature

 Competitive Analysis:

The global cancer immunotherapy market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cancer immunotherapy market for global, Europe, North America, Asia Pacific and South America.

Market Segmentation:

The global cancer immunotherapy market is segmented based on basis of product type, cancer type, end users and geography
Based on product, the global cancer immunotherapy is segmented into monoclonal antibody, immunomodulators, cell therapies, checkpoint inhibitors, vaccines. Monoclonal antibody is further sub-segmented into bispecific monoclonal antibody, naked monoclonal antibody, conjugated monoclonal antibodies and antibody- cytokine fusion proteins.

Immunomodulator is further sub segmented into cytokines, granulocyte macrophage colony stimulating factor (GM-CSF) and oncolytic viruses. The cytokines is further sub-segmented into interferons and interleukins. Cell therapies are further sub-segmented into chimeric antigen receptor T-cell Therapy (CAR T-cell Therapy) and dendritic cell therapies. Checkpoint inhibitors are further sub-segmented into cytotoxic T-lymphocyte associated protein-4, programmed death-1 and programmed death ligand-1 (PD-L1). Vaccine is further sub segmented into therapeutics and prophylactic vaccines. Vaccines are further sub-segmented into therapeutic and prophylactic vaccines.

On the basis of cancer type, the global cancer immunotherapy market is classified into melanoma, lung cancer, head and neck cancer, prostate cancer, breast cancer, multiple myeloma, colorectal cancer.

On the basis of end users, the global cancer immunotherapy market is segmented into hospitals, oncology centers, community healthcare and others.

Based on geography, the global cancer immunotherapy market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa.

Some of the major countries covered in this report are:-

U.S.,
Canada,
Germany,
France,
U.K.,
Netherlands,
Switzerland,
Turkey,
Russia,
China,
India,
South Korea,
Japan,
Australia,
Singapore,
Saudi Arabia,
South Africa
Brazil
among others.

Inquire Regarding This Report @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-immunotherapy-market

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.